Suggested remit: To appraise the clinical and cost effectiveness of 12 standardised quality house dust mite sublingual immunotherapy (12 SQ-HDM SLIT) within its marketing authorisation for treating allergic rhinitis caused by house dust mites in children aged 5 to 11 years.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6510
Provisional Schedule
- Committee meeting:
- 17 June 2026
- Expected publication:
- 26 August 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- ALK-Abello
- Others
- Department of Health and Social Care
- NHS England
- Professional groups
- British Thoracic Society
- ENT UK
- Royal College of Pathologists
- Royal College of Physicians
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 November 2025 | Invitation to participate |
| 27 August 2025 - 24 September 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6510 |
| 27 August 2025 | In progress. Scoping commencing |
| 16 April 2025 | Referral |
| 08 October 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 08 October 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual